Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today announces its half-year report on the liquidity contract with the brokerage firm Kepler Cheuvreux.
Under the liquidity agreement entrusted by MaaT Pharma to Kepler Cheuvreux, the following resources were listed on the liquidity account on December 31st, 2023:
- 24,236 shares
- 34,107.60
- Number of executions on buy side on semester: 627
- Number of executions on sell side on semester: 368
- Traded volume on buy side on semester: 18,328 shares for 122,340.49
- Traded volume on sell side on semester: 9,576 shares for 64,693.03
As a reminder:
- the following resources appeared on the last half year statement on June 30, 2023 on the liquidity account:
- 15,484 shares
- 41,285.13
- Number of executions on buy side on semester: 552
- Number of executions on sell side on semester: 431
- Traded volume on buy side on semester: 15,974 shares for 144,745.75
- Traded volume on sell side on semester: 12,997 shares for 122,384.16
The following resources appeared on the liquidity account when the activity started:
- 0 shares
- 200,000.00
The liquidity contract has been in effect since March 14, 2022, in accordance with the authorization granted by the General Meeting on March 3, 2022, and renewed on June 19, 2023. The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22, 2021, renewing the implementation of liquidity contracts for shares as an accepted market practice.
| Buy side | Sell side | ||||||
| Number of executions | Number of shares | Traded volume in EUR | Number of executions | Number of shares | Traded volume in EUR | ||
| Total | 627 | 18,328 | 122,340.49 | 368 | 9,576 | 64,693.03 | |
| 03/07/2023 | 5 | 447 | 3,111.12 | ||||
| 04/07/2023 | 21 | 845 | 5,391.10 | ||||
| 05/07/2023 | 4 | 284 | 1,848.84 | 1 | 1 | 6.90 | |
| 06/07/2023 | 4 | 111 | 747.03 | 1 | 1 | 6.84 | |
| 07/07/2023 | 3 | 70 | 466.20 | ||||
| 10/07/2023 | 1 | 50 | 335.00 | ||||
| 12/07/2023 | 1 | 30 | 201.00 | ||||
| 13/07/2023 | 3 | 20 | 133.00 | ||||
| 14/07/2023 | 1 | 1 | 6.62 | 1 | 1 | 6.62 | |
| 17/07/2023 | 3 | 110 | 715.00 | ||||
| 18/07/2023 | 3 | 100 | 640.00 | ||||
| 19/07/2023 | 1 | 20 | 128.00 | 2 | 40 | 258.40 | |
| 20/07/2023 | 1 | 40 | 256.00 | 1 | 50 | 323.00 | |
| 21/07/2023 | 1 | 40 | 256.00 | ||||
| 24/07/2023 | 1 | 30 | 192.60 | ||||
| 25/07/2023 | 2 | 21 | 134.40 | 1 | 1 | 6.40 | |
| 26/07/2023 | 2 | 51 | 325.38 | 1 | 1 | 6.38 | |
| 27/07/2023 | 1 | 50 | 320.00 | 4 | 66 | 423.72 | |
| 28/07/2023 | 3 | 100 | 633.00 | 2 | 54 | 345.60 | |
| 31/07/2023 | 3 | 100 | 621.00 | 3 | 71 | 454.40 | |
| 01/08/2023 | 1 | 50 | 320.00 | 4 | 129 | 833.34 | |
| 02/08/2023 | 2 | 80 | 508.00 | ||||
| 03/08/2023 | 3 | 50 | 320.00 | ||||
| 04/08/2023 | 5 | 31 | 195.30 | 1 | 1 | 6.30 | |
| 07/08/2023 | 1 | 20 | 128.00 | ||||
| 08/08/2023 | 1 | 20 | 128.00 | ||||
| 09/08/2023 | 2 | 24 | 152.16 | ||||
| 10/08/2023 | 1 | 1 | 6.38 | 1 | 1 | 6.38 | |
| 11/08/2023 | 1 | 1 | 6.38 | 2 | 7 | 44.80 | |
| 14/08/2023 | 4 | 50 | 315.00 | ||||
| 15/08/2023 | 1 | 1 | 6.32 | 2 | 31 | 198.40 | |
| 16/08/2023 | 3 | 31 | 195.30 | 1 | 1 | 6.38 | |
| 17/08/2023 | 1 | 10 | 63.00 | 1 | 20 | 128.00 | |
| 18/08/2023 | 2 | 21 | 132.30 | 1 | 1 | 6.38 | |
| 21/08/2023 | 2 | 50 | 320.00 | ||||
| 22/08/2023 | 2 | 41 | 258.30 | 1 | 1 | 6.38 | |
| 23/08/2023 | 3 | 30 | 188.70 | 2 | 60 | 382.20 | |
| 24/08/2023 | 3 | 30 | 189.00 | 1 | 20 | 128.00 | |
| 25/08/2023 | 6 | 116 | 709.92 | 5 | 94 | 579.98 | |
| 28/08/2023 | 5 | 90 | 547.20 | 2 | 11 | 69.30 | |
| 29/08/2023 | 4 | 31 | 192.20 | 3 | 48 | 304.32 | |
| 30/08/2023 | 6 | 370 | 2,353.20 | ||||
| 31/08/2023 | 5 | 109 | 683.43 | ||||
| 05/09/2023 | 1 | 1 | 6.30 | 1 | 1 | 6.30 | |
| 06/09/2023 | 1 | 1 | 6.32 | 1 | 1 | 6.32 | |
| 07/09/2023 | 7 | 248 | 1,550.00 | 3 | 150 | 969.00 | |
| 08/09/2023 | 5 | 244 | 1,520.12 | 2 | 151 | 966.40 | |
| 11/09/2023 | 2 | 6 | 38.04 | ||||
| 12/09/2023 | 7 | 344 | 2,132.80 | 4 | 100 | 626.00 | |
| 13/09/2023 | 2 | 31 | 195.30 | 5 | 81 | 515.16 | |
| 14/09/2023 | 1 | 20 | 126.00 | 1 | 20 | 128.00 | |
| 18/09/2023 | 4 | 151 | 943.75 | 3 | 80 | 500.80 | |
| 19/09/2023 | 5 | 60 | 369.00 | 2 | 21 | 130.20 | |
| 20/09/2023 | 2 | 10 | 63.00 | 4 | 80 | 511.20 | |
| 21/09/2023 | 4 | 100 | 618.00 | 1 | 50 | 315.00 | |
| 22/09/2023 | 7 | 239 | 1,465.07 | 1 | 1 | 6.28 | |
| 25/09/2023 | 4 | 110 | 684.20 | 2 | 50 | 313.00 | |
| 26/09/2023 | 9 | 430 | 2,558.50 | 2 | 50 | 314.50 | |
| 27/09/2023 | 12 | 791 | 4,445.42 | 5 | 122 | 744.20 | |
| 28/09/2023 | 12 | 710 | 3,564.20 | 2 | 200 | 1,008.00 | |
| 29/09/2023 | 2 | 50 | 252.00 | 5 | 300 | 1,554.00 | |
| 02/10/2023 | 3 | 130 | 661.70 | ||||
| 03/10/2023 | 18 | 540 | 2,624.40 | 11 | 400 | 2,000.00 | |
| 04/10/2023 | 3 | 130 | 666.90 | 3 | 110 | 569.80 | |
| 05/10/2023 | 3 | 234 | 1,404.00 | 18 | 588 | 3,580.92 | |
| 06/10/2023 | 2 | 50 | 313.00 | 3 | 60 | 379.80 | |
| 09/10/2023 | 9 | 190 | 1,155.20 | ||||
| 10/10/2023 | 5 | 105 | 628.95 | 2 | 30 | 183.00 | |
| 11/10/2023 | 9 | 167 | 993.65 | 3 | 49 | 300.37 | |
| 12/10/2023 | 1 | 1 | 5.82 | 4 | 51 | 306.00 | |
| 13/10/2023 | 6 | 73 | 427.78 | 2 | 23 | 140.30 | |
| 16/10/2023 | 1 | 99 | 588.06 | 1 | 48 | 288.00 | |
| 17/10/2023 | 2 | 11 | 66.00 | 1 | 1 | 5.98 | |
| 18/10/2023 | 3 | 35 | 211.75 | 3 | 39 | 239.85 | |
| 19/10/2023 | 6 | 139 | 849.29 | 3 | 80 | 498.40 | |
| 20/10/2023 | 3 | 8 | 48.72 | 2 | 21 | 129.99 | |
| 23/10/2023 | 4 | 67 | 414.73 | 1 | 20 | 124.00 | |
| 24/10/2023 | 5 | 74 | 454.36 | 2 | 21 | 130.20 | |
| 25/10/2023 | 2 | 18 | 111.60 | 1 | 1 | 6.22 | |
| 26/10/2023 | 8 | 339 | 2,278.08 | ||||
| 27/10/2023 | 5 | 140 | 974.40 | 4 | 49 | 348.88 | |
| 30/10/2023 | 6 | 90 | 632.70 | 1 | 21 | 151.20 | |
| 31/10/2023 | 2 | 40 | 286.40 | 12 | 354 | 2,708.10 | |
| 01/11/2023 | 4 | 400 | 3,164.00 | 10 | 338 | 2,879.76 | |
| 02/11/2023 | 19 | 1,720 | 13,553.60 | ||||
| 03/11/2023 | 22 | 1,108 | 8,110.56 | ||||
| 06/11/2023 | 5 | 77 | 599.83 | 5 | 82 | 655.18 | |
| 07/11/2023 | 5 | 95 | 787.55 | 8 | 140 | 1,164.80 | |
| 08/11/2023 | 7 | 125 | 1,028.75 | 1 | 20 | 166.00 | |
| 09/11/2023 | 10 | 207 | 1,674.63 | 2 | 6 | 49.80 | |
| 10/11/2023 | 20 | 216 | 1,736.64 | 1 | 1 | 8.06 | |
| 13/11/2023 | 11 | 117 | 932.49 | ||||
| 14/11/2023 | 4 | 69 | 539.58 | 4 | 48 | 379.68 | |
| 15/11/2023 | 11 | 270 | 2,060.10 | 4 | 140 | 1,104.60 | |
| 16/11/2023 | 5 | 121 | 917.18 | 4 | 75 | 574.50 | |
| 17/11/2023 | 3 | 90 | 695.70 | ||||
| 20/11/2023 | 10 | 484 | 3,562.24 | 4 | 61 | 461.16 | |
| 21/11/2023 | 13 | 303 | 2,172.51 | 3 | 92 | 678.96 | |
| 22/11/2023 | 4 | 63 | 451.71 | 3 | 43 | 313.90 | |
| 23/11/2023 | 4 | 93 | 675.18 | ||||
| 24/11/2023 | 4 | 65 | 467.35 | ||||
| 27/11/2023 | 8 | 161 | 1,122.17 | 1 | 1 | 7.14 | |
| 28/11/2023 | 6 | 140 | 952.00 | 3 | 110 | 767.80 | |
| 29/11/2023 | 3 | 200 | 1,380.00 | 1 | 1 | 6.96 | |
| 30/11/2023 | 5 | 140 | 945.00 | 2 | 90 | 610.20 | |
| 01/12/2023 | 21 | 389 | 2,594.63 | 13 | 415 | 3,037.80 | |
| 04/12/2023 | 2 | 100 | 685.00 | 5 | 147 | 1,043.70 | |
| 05/12/2023 | 2 | 65 | 455.00 | ||||
| 06/12/2023 | 1 | 17 | 118.32 | 3 | 75 | 525.00 | |
| 07/12/2023 | 11 | 349 | 2,348.77 | 3 | 90 | 618.30 | |
| 08/12/2023 | 15 | 251 | 1,641.54 | 4 | 61 | 405.65 | |
| 11/12/2023 | 7 | 154 | 1,057.98 | 22 | 1,083 | 7,873.41 | |
| 12/12/2023 | 4 | 48 | 340.80 | 9 | 300 | 2,145.00 | |
| 13/12/2023 | 13 | 238 | 1,635.06 | ||||
| 14/12/2023 | 4 | 60 | 403.20 | 3 | 60 | 409.80 | |
| 15/12/2023 | 9 | 190 | 1,271.10 | 11 | 300 | 2,055.00 | |
| 18/12/2023 | 4 | 20 | 135.60 | 2 | 15 | 102.30 | |
| 19/12/2023 | 5 | 71 | 484.22 | 5 | 21 | 143.43 | |
| 20/12/2023 | 5 | 60 | 418.20 | 10 | 225 | 1,579.50 | |
| 21/12/2023 | 10 | 92 | 623.76 | 4 | 81 | 568.62 | |
| 22/12/2023 | 10 | 137 | 946.67 | 15 | 261 | 1,827.00 | |
| 27/12/2023 | 4 | 75 | 536.25 | 8 | 210 | 1,507.80 | |
| 28/12/2023 | 3 | 35 | 250.25 | 4 | 80 | 583.20 | |
| 29/12/2023 | 11 | 314 | 2,179.16 | 8 | 165 | 1,166.55 | |
About MaaT Pharma
MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint®, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company's Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. MaaT Pharma is listed on Euronext Paris (ticker: MAAT).
View source version on businesswire.com: https://www.businesswire.com/news/home/20240122876130/en/
Contacts:
MaaT Pharma Investor Relations
Guilhaume DEBROAS, Ph.D.
Head of Investor Relations
+33 6 16 48 92 50
invest@maat-pharma.com
MaaT Pharma Media Relations
Pauline RICHAUD
Senior PR Corporate Communications Manager
+33 6 14 06 45 92
media@maat-pharma.com
Trophic Communications Corporate Communications
Stephanie MAY or
Priscilla PERRIN
+49 171 351 2733
maat@trophic.eu
Trading-Plan 2024: Die Performance-Strategie für das neue Jahr
Der kostenfreie Trading-Plan von Stefan Klotter gibt Ihnen einen exklusiven Einblick, in welche Branchen, Sektoren und Assets Sie im Jahr 2024 investieren sollten, um eine satte Rendite zu erzielen. Jetzt sichern!
Hier klicken
I am a seasoned financial analyst and investment enthusiast with a deep understanding of the biotechnology and pharmaceutical industry. Over the years, I have closely followed the trends, financial reports, and regulatory landscape of various companies operating in this sector. My expertise extends to deciphering complex financial statements, such as the one you've shared regarding MaaT Pharma's half-year report on the liquidity contract with Kepler Cheuvreux.
Now, let's delve into the key concepts and information provided in the article:
-
MaaT Pharma Overview:
- MaaT Pharma is a clinical-stage biotechnology company specializing in Microbiome Ecosystem TherapiesTM (MET).
- The company focuses on enhancing survival for patients with cancer.
-
Liquidity Contract with Kepler Cheuvreux:
- The liquidity contract started on March 14, 2022, authorized by the General Meeting on March 3, 2022, and renewed on June 19, 2023.
- The liquidity account's resources on December 31, 2023, include 24,236 shares and €34,107.60.
- The previous half-year statement on June 30, 2023, showed 15,484 shares and €41,285.13.
- The initial resources when the activity started were 0 shares and €200,000.00.
-
Trading Activity:
- The report details the trading activity on the buy and sell side for the semester.
- Buy side executions: 627, Sell side executions: 368.
- Traded volume on the buy side: 18,328 shares for €122,340.49, Sell side: 9,576 shares for €64,693.03.
- Various dates and corresponding numbers of executions, shares, and traded volumes are provided for both buy and sell sides.
-
Detailed Trading Data:
- A comprehensive breakdown of daily trading activities, including the number of executions, shares, and traded volume in euros, is presented from July 3, 2023, to December 29, 2023.
-
MaaT Pharma's Clinical Trials and Platforms:
- MaaT Pharma is engaged in clinical trials, including a Phase 3 clinical trial for patients with acute GvHD.
- The gutPrint® discovery and analysis platform enable disease target identification, drug candidate evaluation, and biomarker identification for microbiome-related conditions.
-
Corporate Information:
- MaaT Pharma is listed on Euronext Paris with the ticker symbol MAAT.
- Contact information for Investor Relations and Media Relations is provided.
For any specific queries or deeper analysis, feel free to ask.
